尽管前列腺磁共振成像 (MRI) 越来越多地用于前列腺癌 (PCa) 的诊断和分期，但 MRI 对该疾病可见性的生物学和临床意义尚不清楚。我们的目的是检查有关 PCa MRI 可见性的分子相关性的现有知识。截至 2023 年 11 月，对 PubMed、Scopus 和 Web of Science 数据库进行了查询。我们根据前列腺成像报告定义了 MRI 可见病变和 MRI 不可见病变和数据系统（PI-RADS）评分，并根据基因组、转录组和蛋白质组特征进行比较。从2015年的个人记录中，选择了25个进行定性数据合成。目前的证据支持 MRI 可见性的多基因性质，主要受到与基质、粘附和细胞组织相关的基因的影响。与 MRI 可见度相关的几个基因特征与肿瘤学结果相关，这支持以 PI-RADS 4-5 病变出现的肿瘤含有致命疾病。因此，通过系统活检检测到的 MRI 不可见肿瘤通常侵袭性较小，且预后较好。然而，一些 MRI 不可见的肿瘤具有生物侵袭性 PCa 的分子特征。在市售的预后基因组中，只有 Decipher 与 MRI 可视性密切相关。高 PI-RADS 评分与生物学和临床上侵袭性 PCa 分子表型相关，并且有可能用作生物标志物。然而，MRI 看不见的病变可能存在不良特征，建议继续使用全身活检。需要进一步研究以完善成像数据与预后评估的整合。前列腺癌的磁共振成像可见性是一种多基因特征。较高的前列腺成像报告和数据系统评分与生物学和临床侵袭性癌症的特征相关。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Although prostate magnetic resonance imaging (MRI) is increasingly used to diagnose and stage prostate cancer (PCa), the biologic and clinical significance of MRI visibility of the disease is unclear. Our aim was to examine the existing knowledge regarding the molecular correlates of MRI visibility of PCa.The PubMed, Scopus, and Web of Science databases were queried through November 2023. We defined MRI-visible and MRI-invisible lesions based on the Prostate Imaging Reporting and Data System (PI-RADS) score, and compared these based on the genomic, transcriptomic, and proteomic characteristics.From 2015 individual records, 25 were selected for qualitative data synthesis. Current evidence supports the polygenic nature of MRI visibility, primarily influenced by genes related to stroma, adhesion, and cellular organization. Several gene signatures related to MRI visibility were associated with oncologic outcomes, which support that tumors appearing as PI-RADS 4-5 lesions harbor lethal disease. Accordingly, MRI-invisible tumors detected by systematic biopsies were, generally, less aggressive and had a more favorable prognosis; however, some MRI-invisible tumors harbored molecular features of biologically aggressive PCa. Among the commercially available prognostic gene panels, only Decipher was strongly associated with MRI visibility.High PI-RADS score is associated with biologically and clinically aggressive PCa molecular phenotypes, and could potentially be used as a biomarker. However, MRI-invisible lesions can harbor adverse features, advocating the continued use of systemic biopsies. Further research to refine the integration of imaging data to prognostic assessment is warranted.Magnetic resonance imaging visibility of prostate cancer is a polygenic trait. Higher Prostate Imaging Reporting and Data System scores are associated with features of biologically and clinically aggressive cancer.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.